<p>MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease</p>-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease

Published:2020-01 Issue: Volume:Volume 12 Page:1-13
ISSN:1179-1519
Container-title:Open Access Journal of Clinical Trials
language:en
Short-container-title:OAJCT

Author:

Decourt Boris,Wilson Jeffrey,Ritter Aaron,Dardis Christopher,DiFilippo Frank,Zhuang Xiaowei,Cordes Dietmar^ORCID,Lee Garam,Fulkerson Nadia,St Rose Tessa,Hartley Katurah,Sabbagh Marwan

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer’s Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy;Neurochemical Research;2024-06-06

2. Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond;Current Neuropharmacology;2024-05

3. Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies;Medicinal Research Reviews;2024-03-26

4. Implicative role of cytokines in neuroinflammation mediated AD and associated signaling pathways: Current progress in molecular signaling and therapeutics;Ageing Research Reviews;2023-12

5. Cancer drugs with high repositioning potential for Alzheimer’s disease;Expert Opinion on Emerging Drugs;2023-10-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP